Related Experiment Video
Updated: Sep 10, 2025
05:30
Controlled Cortical Impact Model for Traumatic Brain Injury
Published on: August 5, 2014
28.8K
Management of Traumatic Brain Injury Sequelae With Alpha-2 Adrenergic Receptor Agonists
Jamie L Ott1, Thomas K Watanabe
1Author Affiliations: Department of Physical Medicine and Rehabilitation, University of Washington, Seattle, Washington (Dr Ott); and Clinical Director - Drucker Brain Injury Center, Co-Director - Stroke Rehabilitation Program, Jefferson Moss-Magee Rehabilitation, Elkins Park, Pennsylvania (Dr Watanabe).
The Journal of Head Trauma Rehabilitation
|August 22, 2025
Summary
Alpha-2 receptor agonists offer various clinical uses for managing symptoms after traumatic brain injury (TBI). Emerging research continues to refine understanding of these medications for TBI treatment.
Area of Science:
- Pharmacology
- Neurology
- Traumatology
Background:
- Traumatic brain injury (TBI) can lead to complex sequelae requiring diverse treatment strategies.
- Alpha-2 receptor agonists are a class of medications with established roles in various medical conditions.
- Clinicians frequently encounter or consider alpha-2 agonists for patients with TBI.
Purpose of the Study:
- To review the clinical applications of alpha-2 receptor agonists in managing the consequences of TBI.
- To provide clinicians with an overview of the utility and considerations for using these agents in TBI patients.
Main Methods:
- This study employed a narrative review methodology.
- Literature search focused on alpha-2 agonists and their relevance to TBI sequelae.
Main Results:
- Alpha-2 receptor agonists possess a range of indications and potential side effects.
- Specific properties of individual drugs within this class influence clinical decision-making for TBI management.
Conclusions:
- Alpha-2 receptor agonists represent a valuable therapeutic option for certain TBI-related conditions.
- Ongoing research provides new insights into the effective use of alpha-2 agonists in TBI care.
Related Concept Videos
01:30Adrenergic Agonists: Therapeutic Uses
947
Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
947
01:25Cardiopulmonary Resuscitation IV: Pharmacological Management
75
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
75
01:22Alzheimer's Disease: Treatment
260
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
260
01:22Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
960
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
960
01:30Indirect-Acting Cholinergic Agonists: Pharmacological Actions
828
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
828
01:11Direct-Acting Cholinergic Agonists: Therapeutic Uses
873
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
873